布地奈德福莫特罗联合噻托溴铵治疗COPD的效果分析
|
摘要
目的观察布地奈德福莫特罗联合噻托溴铵治疗慢性阻塞性肺疾病(COPD)的临床效果。方法 80例COPD患者,采用随机数字抽取法分为对照组和观察组,每组40例。对照组患者采用布地奈德福莫特罗粉吸入剂治疗,观察组患者在对照组基础上增加噻托溴铵治疗,比较两组患者治疗效果。结果治疗前,两组患者最大肺活量(VCmax)、第1秒用力呼气容积(FEV1)、最高呼气流量(PEF)、FEV1/占用力肺活量百分比(FEV1/FVC)水平比较,差异无统计学意义(P>0.05);治疗后,观察组患者VCmax、FEV1、PEF、FEV1/FVC水平分别为(2.68±0.44)L、(2.02±0.23)L、(4.89±0.66)L/s、(74.96±6.59)%,均优于对照组的(2.15±0.48)L、(1.64±0.36)L、(3.56±0.34)L/s、(68.31±7.57)%,差异具有统计学意义(P<0.05)。结论布地奈德福莫特罗联合噻托溴铵能够明显改善COPD患者的肺功能,值得临床推广应用。
Objective To observe the clinical effect of budesonide formoterol combined with tiotropium bromide in the treatment of chronic obstructive pulmonary disease(COPD). Methods A total of 80 COPD patients were divided by random number table method into control group and observation group, with 40 cases in each group. The control group was treated with budesonide formoterol powder inhaler, and the observation group was treated with tiotropium bromide on the basis of the control group. The treatment effect in two groups was compared. Results Before treatment, both groups had no statistically significant difference in maximum vital capacity(VCmax), forced expiratory volume in 1 second(FEV1), peak expiratory flow(PEF) and FEV1/forced vital capacity(FEV1/FVC)(P>0.05). After treatment, the observation group had better VCmax, FEV1, PEF and FEV1/FVC level respectively as(2.68±0.44) L,(2.02±0.23) L,(4.89±0.66) L/s and(74.96±6.59)% than(2.15± 0.48) L,(1.64±0.36) L,(3.56±0.34) L/s and(68.31±7.57)% in the control group, and their difference was statistically significant(P<0.05). Conclusion Combination of budesonide formoterol and tiotropium bromide can obviously improve the lung function of COPD patients, and it is worthy of clinical promotion and application.
Objective To observe the clinical effect of budesonide formoterol combined with tiotropium bromide in the treatment of chronic obstructive pulmonary disease(COPD). Methods A total of 80 COPD patients were divided by random number table method into control group and observation group, with 40 cases in each group. The control group was treated with budesonide formoterol powder inhaler, and the observation group was treated with tiotropium bromide on the basis of the control group. The treatment effect in two groups was compared. Results Before treatment, both groups had no statistically significant difference in maximum vital capacity(VCmax), forced expiratory volume in 1 second(FEV1), peak expiratory flow(PEF) and FEV1/forced vital capacity(FEV1/FVC)(P>0.05). After treatment, the observation group had better VCmax, FEV1, PEF and FEV1/FVC level respectively as(2.68±0.44) L,(2.02±0.23) L,(4.89±0.66) L/s and(74.96±6.59)% than(2.15± 0.48) L,(1.64±0.36) L,(3.56±0.34) L/s and(68.31±7.57)% in the control group, and their difference was statistically significant(P<0.05). Conclusion Combination of budesonide formoterol and tiotropium bromide can obviously improve the lung function of COPD patients, and it is worthy of clinical promotion and application.
引文
[1]刘鹏珍,宋春钰,刘艳芹.噻托溴铵联合信必可都保吸入剂治疗COPD稳定期的疗效观察.临床肺科杂志, 2013, 18(3):544.
[2]林卫涵,吴卫锋.噻托溴铵与布地奈德福莫特罗粉联合吸入在重度、极重度COPD稳定期中的疗效观察.中国现代药物应用,2013, 7(11):9-11.
[3]田玉恒,马原,陈书文.地奈德/福莫特罗粉剂联合噻托溴铵治疗稳定期慢性阻塞性肺疾病的疗效探究.中国现代药物应用, 2014, 8(19):124-125.
[4]刘勇,解玉东.布地奈德/福莫特罗干粉吸入剂联合噻托溴铵治疗中重度稳定期COP疗效评价.中国实用医药, 2013, 8(16):165-166.
[5]叶青,张立波,范荣梅,等.布地奈德福莫特罗联合噻托溴铵对重度慢性阻塞性肺疾病稳定期患者的疗效分析.中华肺部疾病杂志(电子版), 2014, 7(3):45-48.
[6]魏亚强,赵红.布地奈德/福莫特罗粉剂联合噻托溴铵粉剂吸入治疗稳定期慢性阻塞性肺疾病临床研究.陕西医学杂志,2012, 41(7):880-881.
[7]杨雪梅,王卫平.布地奈德福莫特罗联合噻托溴铵治疗慢性阻塞性肺疾病效果分析.中国医药, 2015, 10(11):1596-1598.
[8]张继贤,姜益,赵莺.噻托溴铵联合布地奈德/福莫特罗吸入治疗慢性阻塞性肺疾病的临床分析.中国医师进修杂志, 2014,37(28):66-68.
[9]瞿美君,曹奇峰.布地奈德/福莫特罗联合噻托溴铵治疗稳定期慢性阻塞性肺疾病疗效观察.药物流行病学杂志, 2015(7):394-396.
[2]林卫涵,吴卫锋.噻托溴铵与布地奈德福莫特罗粉联合吸入在重度、极重度COPD稳定期中的疗效观察.中国现代药物应用,2013, 7(11):9-11.
[3]田玉恒,马原,陈书文.地奈德/福莫特罗粉剂联合噻托溴铵治疗稳定期慢性阻塞性肺疾病的疗效探究.中国现代药物应用, 2014, 8(19):124-125.
[4]刘勇,解玉东.布地奈德/福莫特罗干粉吸入剂联合噻托溴铵治疗中重度稳定期COP疗效评价.中国实用医药, 2013, 8(16):165-166.
[5]叶青,张立波,范荣梅,等.布地奈德福莫特罗联合噻托溴铵对重度慢性阻塞性肺疾病稳定期患者的疗效分析.中华肺部疾病杂志(电子版), 2014, 7(3):45-48.
[6]魏亚强,赵红.布地奈德/福莫特罗粉剂联合噻托溴铵粉剂吸入治疗稳定期慢性阻塞性肺疾病临床研究.陕西医学杂志,2012, 41(7):880-881.
[7]杨雪梅,王卫平.布地奈德福莫特罗联合噻托溴铵治疗慢性阻塞性肺疾病效果分析.中国医药, 2015, 10(11):1596-1598.
[8]张继贤,姜益,赵莺.噻托溴铵联合布地奈德/福莫特罗吸入治疗慢性阻塞性肺疾病的临床分析.中国医师进修杂志, 2014,37(28):66-68.
[9]瞿美君,曹奇峰.布地奈德/福莫特罗联合噻托溴铵治疗稳定期慢性阻塞性肺疾病疗效观察.药物流行病学杂志, 2015(7):394-396.